Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
暂无分享,去创建一个
M. Ladanyi | C. Sima | M. Kris | C. Azzoli | W. Pao | M. Arcila | Gregory Riely | V. Miller | Y. Janjigian | G. Oxnard | S. Kass